Sorry, you need to enable JavaScript to visit this website.

Node Banner

Rare Diseases > Endocrine Disorders

Please note that some measures are designed to be used for clinical research for outcome
assessment and some measures are designed to be used as a screening tool.

Pain Assessed Acromegaly Symptom Questionnaire (PASQ)

Click Thumbnail to Review

Pain Assessed Acromegaly Symptom Questionnaire (PASQ)

Description and Context of Use
The PASQ measures the symptoms of Acromegaly.
Population age range
Adults (18-65)
Number of items
6
Recall Period
During the past week including today
Response Scales
Numerical rating scale
Administration Mode
Self-administered; Paper and pen
Administration Time
5 minutes
References
Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007; 156: 75-82.

Sievers C, Brübach K, Saller B, Schneider HJ, Buchfelder M, Droste M, Mann K, Strasburger C, Stalla GK. Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). Clin Endocrinol 2010; 73: 89-94.
Original Language
English (US)
*Select Available Language(s):
*Required
Select language
- Please check the fields in red.
- You must agree the Terms of Use.

Form Must
Be Completed